Amgen看好生物製藥! 增持半新股Neumora獲利近兩倍
Amgen(AMGN.US)向美國證券交易委員會提交的13D文件中表示,Amgen持有9月中上市的生物製藥公司Neumora Therapeutics(NMRA.US)共3,540萬股持股,佔已發行股份的23.2%。
Amgen以約1.1億美元購買Neumora優先股,隨著Neumora首次公開招股於9月19日結束,優先股轉換為3,360萬股Neumora普通股,Amgen再於9月19日追加投資3,000萬美元,以每股17美元價格增持約 180萬股普通股。
Amgen已花費約1.4億美元持有Neumora股份,據Neumora周二收市價11.71美元計算,Amgen持股已升值至4.142億美元,持股賺獲195.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.